Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction - Trial NCT05984134
Access comprehensive clinical trial information for NCT05984134 through Pure Global AI's free database. This Phase 2 trial is sponsored by Beijing Northland Biotech. Co., Ltd. and is currently Completed. The study focuses on Acute Myocardial Infarction. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Northland Biotech. Co., Ltd.
Timeline & Enrollment
Phase 2
Jul 15, 2022
May 29, 2023
Primary Outcome
Percentage change of myocardial infarction area
Summary
A multicenter randomized double-blind placebo parallel control design was used in this study.
 The 90 participants were randomly assigned to placebo, 0.5ฮผg/kg dose group, and 1.0ฮผg/kg dose
 group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo
 intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90
 days after PCI.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05984134
Non-Device Trial